Erratum: Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma (Journal of Gastroenterology (2012) DOI: 10.1007/s00535-011-0492-9);Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma

Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 421-426

  Kinugasa, Hideaki ^a   Nouso, Kazuhiro ^a   Takeuchi, Yasuto ^a   Yasunaka, Tetsuya ^a   Onishi, Hideki ^a   Nakamura, Shin Ichiro ^a   Shiraha, Hidenori ^a   Kuwaki, Kenji ^a   Hagihara, Hiroaki ^a   Ikeda, Fusao ^a   Miyake, Yasuhiro ^a   Takaki, Akinobu ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Early stage HCC; Hepatocellular carcinoma; Small HCC; TACE

Indexed keywords

IODINATED POPPYSEED OIL;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME; UNIVERSITY HOSPITAL;

EID: 84863084081     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0508-5     Document Type: Erratum

References (24)

1. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions: of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35:421-30.
3. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51. (Pubitemid 350182575)
4. Kudo M, Okanoue T. Japan Society of Hepatology Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72:S2-15.
5. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-94.
6. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg. 2005;242:36-42.
7. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablation therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-8. (Pubitemid 43327762)
8. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma. Cancer. 2010;116:3638-44.
9. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258: 627-34.
10. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg. 2011;18:413-20.
11. Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer. 2001;91:949-56.
12. Imamura H, Matsuyama Y, Yanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7. (Pubitemid 36169630)
13. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamasaki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44: 1518-27. (Pubitemid 44953657)
14. Kudo M. Hobyung Chung. Single HCC between 2 and 5 cm: the gray zone. J Hepatobiliary Pancreat Sci. 2010;17:434-7.
15. Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52-8. (Pubitemid 34304387)
16. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Caner. 2008;98:1161-5. (Pubitemid 351481668)
17. Arimura E, Kotoh K, Nakamuta M, Morizono S, Enjoji M, Nawata H. Local recurrence is an important prognostic factor of hepatocellular carcinoma. World J Gastroenterol. 2005;11: 5601-6. (Pubitemid 41684910)
18. Chung JW, Kim HC, Yoon HS, Lee HS, Jae HJ, Lee W, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. Korean J Radiol. 2006;7:257-66. (Pubitemid 44905084)
19. Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotake H, et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg. 2002;9:469-77. (Pubitemid 36305083)
20. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997;79:2087-94. (Pubitemid 27227372)
21. Livraghi T. Single HCC smaller than 2 cm: surgery or ablation. J Hepatobiliary Pancreat Sci. 2010;17:425-9.
22. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto K, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alphafetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2001;16:1290-6. (Pubitemid 34088278)
23. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734-9. (Pubitemid 34607087)
24. Nouso K, Matumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453-8. (Pubitemid 351342067)